Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Braglia
Enrico Braglia, Pazzallo CH
| Patent application number | Description | Published |
|---|---|---|
| 20110178118 | PALONOSETRON FOR THE TREATMENT OF CHEMOTHERAPY INDUCED EMESES - Methods and compositions for reducing chemotherapy and radiotherapy induced emises with 5-HT | 07-21-2011 |
| 20110192493 | Liquid Pharmaceutical Formulations of Palonosetron - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 08-11-2011 |
Enrico Braglia, Lugano-Pazzallo CH
| Patent application number | Description | Published |
|---|---|---|
| 20100105724 | CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE - Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms. | 04-29-2010 |
Marco Braglia, Torino IT
| Patent application number | Description | Published |
|---|---|---|
| 20090174500 | Continously Tunable Delay Line - A tunable delay line for radiofrequency applications includes a waveguide and a dielectric perturbing member that is displaceable relative to the waveguide for varying the delay imparted by the line. The waveguide is a ridge waveguide and the perturbing member is arranged parallel to a longitudinal end surface of the ridge and is movable in the ridge plane, toward and away from the ridge end surface, or in a direction transversal to the ridge. | 07-09-2009 |
Marco Braglia, Parma IT
| Patent application number | Description | Published |
|---|---|---|
| 20110126595 | FOREHEARTH OR WORKING-END FOR GLASS FURNACE AND PROCEDURE FOR THE EXTRACTION OF FUMES FROM THE FOREHEARTH - A forehearth ( | 06-02-2011 |
Riccardo Braglia, Pazzallo CH
| Patent application number | Description | Published |
|---|---|---|
| 20110192493 | Liquid Pharmaceutical Formulations of Palonosetron - The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments. | 08-11-2011 |
Riccardo Braglia, Lugano-Pazzallo CH
| Patent application number | Description | Published |
|---|---|---|
| 20100105724 | CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE - Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms. | 04-29-2010 |
Riccardo Braglia, Lugano-Carabbia CH
| Patent application number | Description | Published |
|---|---|---|
| 20100261734 | Methods of Treating Bladder Dysfunction Using Netupitant - The present invention relates to methods for reducing the frequency of bladder contractions without significantly affecting micturition pressure, comprising administering a pharmaceutical composition comprising a therapeutically effective amount of netupitant, or a pharmaceutically acceptable salt or prodrug thereof. The method can be used to treat bladder dysfunction without significantly increasing residual volume, including urgency, frequency, pollakiuria, nocturia, low deferment time, suboptimal volume threshold, neurogenic bladder, or combinations thereof. | 10-14-2010 |
| 20100317581 | Ipamorelin Diacetate Injection and Infusion Solutions - Injection and infusion solutions of ipamorelin, having the following composition: | 12-16-2010 |